New Aerosol Delivery Devices for Cystic Fibrosis

Kesser, Kenneth C.; Geller, David E.
June 2009
Respiratory Care;Jun2009, Vol. 54 Issue 6, p754
Academic Journal
Cystic fibrosis (CF) patients use several therapies to treat chronic inflammation and infection in the lungs and to improve airway clearance. Inhaled therapies in CF typically include bronchodilators, airway wetting agents, mucus-active agents, and antibiotics, among others. There are many variables to take into account when prescribing aerosolized therapies to CF patients, including aerosol factors, patient variables (eg, age, disease severity, and breathing patterns), and the limitations of current aerosol delivery systems. The greatest challenge for patients is dealing with the time burden placed on them to try to fit all the treatments into their day-a burden that is likely to be even greater in the near future due to the exciting pipeline of novel therapies that target the genetic defect of CF as well as the pathophysiologic consequences. Fortunately, novel aerosol delivery systems and drug formulations are being developed to tackle the many challenges of aerosol delivery in CF. If successful, these systems will reduce the time burden and improve the clinical outcomes for the CF community.


Related Articles

  • Nebulized Antibiotics in Cystic Fibrosis. Sermetgaudelus, I.; Lecocguic, Y.; Ferroni, A.; Clairicia, M.; Barthe, J.; Delaunay, J.; Brousse, V.; Lenoir, G. // Pediatric Drugs;2002, Vol. 4 Issue 7, p455 

    Nebulization is a useful administration route in cystic fibrosis (CF) as it delivers antibiotics directly to the endobronchial site of infection and is associated with decreased toxicity because of limited systemic absorption. It is assumed that the concentration of antibiotics in bronchial...

  • Clinical trial to test success of cystic fibrosis lung infection treatment.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that the intravenous antibiotics are being tested for treating cystic fibrosis complications effectively in patients with lung infection.

  • Aerosol Antibiotics in Cystic Fibrosis. Geller, David E. // Respiratory Care;May2009, Vol. 54 Issue 5, p658 

    Chronic airways infection and inflammation is the greatest source of morbidity and mortality in cystic fibrosis (CF) patients. Many organisms can be found in the lower respiratory tract of CF patients, but infection with mucoid Pseudomonas aeruginosa is common, is associated with poorer...

  • A New Bronchodilator Aerosol: Its Effectiveness in Childhood Asthma. Lecks, H. I.; Kravis, Lillian P. // Clinical Pediatrics;Jun1965, Vol. 4 Issue 6, p314 

    This article presents a study on the effectiveness of an aerosol bronchodilating agent, the Warner-Lambert W-2348 plastic nebulizer, in treating children with asthma. This device dispenses an aerosol whose principal therapeutic ingredients are the bronchodilator isoproterenol and a wetting...

  • Silastic catheters for home antibiotic therapy in patients with cystic fibrosis. Buck, C.; Holl, R.; Kohne, E.; Wolf, A. // European Journal of Pediatrics;1997, Vol. 156 Issue 3, p209 

    Repeated 14-day courses of intravenous antibiotic therapy for patients with cystic fibrosis (CF), who have been colonized with Pseudomonas aeruginosa (PA), is one currently accepted treatment. Conventional intravenous cannulas for antibiotic delivery often have a short line life leading to...

  • Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. Sutton, Morgan T.; Fletcher, David; Ghosh, Santosh K.; Weinberg, Aaron; van Heeckeren, Rolf; Kaur, Sukhmani; Sadeghi, Zhina; Hijaz, Adonis; Reese, Jane; Lazarus, Hillard M.; Lennon, Donald P.; Caplan, Arnold I.; Bonfield, Tracey L. // Stem Cells International;1/26/2016, p1 

    Cystic fibrosis (CF) is a genetic disease in which the battle between pulmonary infection and inflammation becomes the major cause of morbidity and mortality. We have previously shown that human MSCs (hMSCs) decrease inflammation and infection in the in vivo murine model of CF. The studies in...

  • New Cystic Fibrosis Medications. Lillie, Brendan // RT: The Journal for Respiratory Care Practitioners;Mar2013, Vol. 26 Issue 3, p12 

    The article focuses on certain advances in the development of medication for the treatment of cystic fibroid (CF). Several forms of aerosol antibiotics like polymyxins, aminoglycosides and fluroquinolones are being developed. The article also discusses endotracheal intubation, mechanical...

  • Inhaled hypertonic saline in cystic fibrosis.  // Archives of Disease in Childhood;Jun2006, Vol. 91 Issue 6, p468 

    The article looks at two studies on the effectiveness of regular inhalation of hypertonic saline in young patients with cystic fibrosis. In Australia, 164 patients inhaled saline twice a day for 48 weeks. In the United States, 24 patients inhaled nebulized hypertonic saline four times daily for...

  • New therapeutic key for cystic fibrosis: a role for lipoxins. Takai, Daiya; Nagase, Takahide; Shimizu, Takao // Nature Immunology;Apr2004, Vol. 5 Issue 4, p357 

    Suggests the role of lipoxins as a therapeutic key in the management of cystic fibrosis (CF). Development of lung infections with Pseudomonas aeruginosa, which eventually compromises lung function, a hallmark of CF; Identification of the CF Transmembrane conductance regulator (CFTR) as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics